As detailed in Supplementary Table S1, the thymomas in non-responders were predominantly of types B1 and B2, which are known to be associated with a more robust lymphocytic component and potentially greater CD4 + CD8 + double-positive T-cell activity (24), suggests that TAMG is driven by a more complex autoimmune response involving prominent and persistent T-cell mediated autoimmunity (25, 26), against which FcRn antagonism may have limited efficacy. The gene discussed is CD4; the disease is thymoma.